⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427153 | 1.00 | — | — | |
| SCHEMBL29217326 | 0.79 | — | — | |
| SCHEMBL1165736 | 0.74 | — | — | |
| SCHEMBL2303127 | 0.74 | — | — | |
| SCHEMBL1662310 | 0.74 | — | — | |
| SCHEMBL28365606 | 0.74 | — | — | |
| SCHEMBL29424874 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL10869316 | 0.72 | IDO1 (0.42) | — | |
| SCHEMBL6869752 | 0.70 | IDO1 (0.50) | — | |
| SCHEMBL1044788 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054187-A1 | TGR5 ANTAGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250074919-A1 | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2025-03-06 | — | — | US | disclosed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-106456619-A | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2017009806-A1 | SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-01-19 | — | — | WO | disclosed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| EP-2569310-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
| WO-2011141848-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-7169193-B2 | Use of sugar surfactants and fatty acid partial glycerides | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20030150069-A1 | Use of sugar surfactants and fatty acid partial glycerides | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2003-08-14 | — | — | US | disclosed |